05:33 AM EDT, 10/14/2026 (MT Newswires) -- Alvotech (ALVO.IC, ALVO-SDB.ST) and pharmaceutical company Advanz Pharma filed an application with the European Medicines Agency for AVT29, a proposed biosimilar to 8 milligrams of Eylea, according to a Wednesday release. The 8 mg formulation of Eylea, which is used to treat certain retinal diseases through injections in the eye, could potentially lower the quantity of maintenance injections and the treatment load for patients. The submission is the first across the globe for a proposed biosimilar to Eylea 8 mg, the biosimilar-focused biotechnology company Alvotech said. Under a partnership agreement, Alvotech is in charge of development and commercial supply of AVT29, while Advanz Pharma oversees its registration and commercialization in Europe.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.